曲奥舒凡暴露的高个体间变异与儿童造血干细胞移植早期毒性相关:一项前瞻性多中心研究
这项前瞻性多中心观察性研究在77例儿童患者中分析曲奥舒凡药代动力学及其与方案相关毒性和早期临床结局的关系。曲奥舒凡第1天暴露的个体间变异分别为56%和33%;高暴露(>1650 mg*h/l)与黏膜毒性和皮肤毒性风险增加相关,但与植入、急性移植物抗宿主病和供者嵌合率无相关性。
要点
- 儿童曲奥舒凡药代动力学个体间变异大,第1天暴露变异分别为56%和33%。
- 高曲奥舒凡暴露(>1650 mg*h/l)与黏膜毒性和皮肤毒性风险增加相关。
- 曲奥舒凡暴露与植入、急性移植物抗宿主病和供者嵌合率无相关性。
核心结论
- 研究首次在大型儿童队列中提供证据,显示曲奥舒凡药代动力学存在高变异,且曲奥舒凡暴露与早期毒性相关。
- 正在进行的研究将揭示曲奥舒凡暴露是否与长期疾病特异性结局和晚期治疗相关毒性有关。
研究设计与样本
- 前瞻性多中心观察性研究,纳入77例儿童患者。
- 曲奥舒凡剂量:<1岁婴儿(n=12)为30 g/m2,连续3天给药;≥1岁儿童(n=65)为42 g/m2。
主要发现
- 第1天曲奥舒凡平均暴露:10 g/m2组为1744 ± 795 mg*h/l,14 g/m2组为1561 ± 511 mg*h/l;两组个体间变异分别为56%和33%。
- 高曲奥舒凡暴露(>1650 mg*h/l)与黏膜毒性风险增加相关(OR 4.40;95%CI 1.19-16.28,P=0.026)。
- 高曲奥舒凡暴露(>1650 mg*h/l)与皮肤毒性风险增加相关(OR 4.51;95%CI 1.07-18.93,P=0.040)。
- 曲奥舒凡暴露与植入、急性移植物抗宿主病和供者嵌合率之间未发现相关性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treosulfan-based conditioning is increasingly employed in paediatric haematopoietic stem cell transplantation (HSCT). Data on treosulfan pharmacokinetics in children are scarce, and the relationship between treosulfan exposure, toxicity and clinical outcome is unresolved. In this multicentre prospective observational study, we studied treosulfan pharmacokinetics and the drug's relationship with regimen-related toxicity and early clinical outcome in 77 paediatric patients. Treosulfan dose was 30 g/m2 , administered over 3 consecutive days in infants <1 year old (n = 12) and 42 g/m2 in children ≥1 year old (n = 65). Mean day 1 treosulfan exposure was 1744 ± 795 mg*h/l (10 g/m2 ) and 1561 ± 511 mg*h/l (14 g/m2 ), with an inter-individual variability of 56 and 33% in the respective groups. High treosulfan exposure (>1650 mg*h/l) was associated with an increased risk of mucosal [Odds ratio (OR) 4·40; 95% confidence interval (CI) 1·19-16·28, P = 0·026] and skin toxicity (OR 4·51; 95% CI 1·07-18·93, P = 0·040). No correlation was found between treosulfan exposure and the early clinical outcome parameters: engraftment, acute graft-versus-host disease and donor chimerism. Our study provides the first evidence in a large cohort of paediatric patients of high variability in treosulfan pharmacokinetics and an association between treosulfan exposure and early toxicity. Ongoing studies will reveal whether treosulfan exposure is related to long-term disease-specific outcome and late treatment-related toxicity.
引用
- van der Stoep MYEC, Bertaina A, Ten Brink MH, et al. High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study. Br J Haematol. 2017. PMID: 29048102. doi:10.1111/bjh.14960
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。